Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.07
AMED's Cash to Debt is ranked lower than
75% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 0.33 vs. AMED: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
AMED' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.36 Max: N/A
Current: 0.07
Equity to Asset 0.58
AMED's Equity to Asset is ranked higher than
67% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 0.46 vs. AMED: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
AMED' s Equity to Asset Range Over the Past 10 Years
Min: -0.31  Med: 0.56 Max: 1
Current: 0.58
-0.31
1
Interest Coverage 6.34
AMED's Interest Coverage is ranked higher than
51% of the 187 Companies
in the Global Medical Care industry.

( Industry Median: 6.17 vs. AMED: 6.34 )
Ranked among companies with meaningful Interest Coverage only.
AMED' s Interest Coverage Range Over the Past 10 Years
Min: 2.93  Med: 16.58 Max: 115.64
Current: 6.34
2.93
115.64
F-Score: 5
Z-Score: 5.49
M-Score: -2.69
WACC vs ROIC
7.57%
7.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 4.52
AMED's Operating margin (%) is ranked lower than
64% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 7.18 vs. AMED: 4.52 )
Ranked among companies with meaningful Operating margin (%) only.
AMED' s Operating margin (%) Range Over the Past 10 Years
Min: -32.02  Med: 6.92 Max: 15.25
Current: 4.52
-32.02
15.25
Net-margin (%) 2.88
AMED's Net-margin (%) is ranked lower than
61% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 4.49 vs. AMED: 2.88 )
Ranked among companies with meaningful Net-margin (%) only.
AMED' s Net-margin (%) Range Over the Past 10 Years
Min: -26.01  Med: 3.98 Max: 9.33
Current: 2.88
-26.01
9.33
ROE (%) 9.75
AMED's ROE (%) is ranked higher than
52% of the 213 Companies
in the Global Medical Care industry.

( Industry Median: 9.52 vs. AMED: 9.75 )
Ranked among companies with meaningful ROE (%) only.
AMED' s ROE (%) Range Over the Past 10 Years
Min: -54.77  Med: 8.54 Max: 20.95
Current: 9.75
-54.77
20.95
ROA (%) 5.74
AMED's ROA (%) is ranked higher than
61% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.79 vs. AMED: 5.74 )
Ranked among companies with meaningful ROA (%) only.
AMED' s ROA (%) Range Over the Past 10 Years
Min: -35.44  Med: 5.47 Max: 12.39
Current: 5.74
-35.44
12.39
ROC (Joel Greenblatt) (%) 151.25
AMED's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 17.56 vs. AMED: 151.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMED' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -327.41  Med: 77.02 Max: 233.27
Current: 151.25
-327.41
233.27
Revenue Growth (3Y)(%) -8.00
AMED's Revenue Growth (3Y)(%) is ranked lower than
85% of the 173 Companies
in the Global Medical Care industry.

( Industry Median: 7.40 vs. AMED: -8.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMED' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -23  Med: 5.10 Max: 35.1
Current: -8
-23
35.1
EPS Growth (3Y)(%) -68.00
AMED's EPS Growth (3Y)(%) is ranked lower than
98% of the 128 Companies
in the Global Medical Care industry.

( Industry Median: 5.90 vs. AMED: -68.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMED' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68  Med: 31.60 Max: 186.7
Current: -68
-68
186.7
» AMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AMED Guru Trades in Q2 2015

Steven Cohen 90,500 sh (New)
Joel Greenblatt 395,393 sh (+900.13%)
Jim Simons 117,200 sh (+73.37%)
Paul Tudor Jones Sold Out
» More
Q3 2015

AMED Guru Trades in Q3 2015

Paul Tudor Jones 7,757 sh (New)
Jim Simons 148,001 sh (+26.28%)
Steven Cohen 52,800 sh (-41.66%)
Joel Greenblatt 137,387 sh (-65.25%)
» More
Q4 2015

AMED Guru Trades in Q4 2015

Joel Greenblatt 345,912 sh (+151.78%)
Jim Simons 348,301 sh (+135.34%)
Steven Cohen 97,300 sh (+84.28%)
Paul Tudor Jones 6,400 sh (-17.49%)
» More
Q1 2016

AMED Guru Trades in Q1 2016

RS Investment Management 802,082 sh (New)
Jim Simons 630,901 sh (+81.14%)
Paul Tudor Jones Sold Out
Steven Cohen 91,900 sh (-5.55%)
Joel Greenblatt 229,703 sh (-33.59%)
» More
» Details

Insider Trades

Latest Guru Trades with AMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care
Compare:ASX:HSO, NAS:LPNT, JSE:NTC, ISX:MIKA, NYSE:THC, LSE:NMC » details
Traded in other countries:ADY.Germany,
Amedisys Inc is a provider of low-cost home health services to the chronic, co-morbid, aging American population. The Company's operations involve servicing patients through its two reportable business segments: home health and hospice.

Amedisys Inc was originally incorporated in Louisiana in 1982. Its operations were transferred to a Delaware corporation, which was incorporated in 1994; and became a publicly traded company in August of that year. The Company is a provider of low-cost home health services to the chronic, co-morbid, aging American population. The operations involve servicing patients through its two reportable business segments: home health and hospice. The home health segment delivers services in the homes of individuals who may be recovering from an illness, injury or surgery. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Individuals with a terminal illness such as heart disease, pulmonary disease, dementia, Alzheimers, HIV/AIDS or cancer may be eligible for hospice care. The Company operates 41 home health care centers and five hospice care centers with care centers servicing the same markets, sold 19 home health care centers and one hospice care center and closed 10 home health care centers. The Companys operations are regulated by Federal, state and local authorities.

Ratios

vs
industry
vs
history
P/E(ttm) 44.50
AMED's P/E(ttm) is ranked lower than
75% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 26.08 vs. AMED: 44.50 )
Ranked among companies with meaningful P/E(ttm) only.
AMED' s P/E(ttm) Range Over the Past 10 Years
Min: 4.64  Med: 17.08 Max: 80.45
Current: 44.5
4.64
80.45
Forward P/E 24.27
AMED's Forward P/E is ranked lower than
81% of the 75 Companies
in the Global Medical Care industry.

( Industry Median: 16.64 vs. AMED: 24.27 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 44.50
AMED's PE(NRI) is ranked lower than
75% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 25.40 vs. AMED: 44.50 )
Ranked among companies with meaningful PE(NRI) only.
AMED' s PE(NRI) Range Over the Past 10 Years
Min: 4.65  Med: 16.85 Max: 79.39
Current: 44.5
4.65
79.39
Price/Owner Earnings (ttm) 39.68
AMED's Price/Owner Earnings (ttm) is ranked lower than
68% of the 88 Companies
in the Global Medical Care industry.

( Industry Median: 26.92 vs. AMED: 39.68 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AMED' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.98  Med: 21.35 Max: 870
Current: 39.68
3.98
870
P/B 4.17
AMED's P/B is ranked lower than
73% of the 217 Companies
in the Global Medical Care industry.

( Industry Median: 2.55 vs. AMED: 4.17 )
Ranked among companies with meaningful P/B only.
AMED' s P/B Range Over the Past 10 Years
Min: 0.5  Med: 1.99 Max: 4.25
Current: 4.17
0.5
4.25
P/S 1.29
AMED's P/S is ranked higher than
58% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. AMED: 1.29 )
Ranked among companies with meaningful P/S only.
AMED' s P/S Range Over the Past 10 Years
Min: 0.19  Med: 0.79 Max: 2.28
Current: 1.29
0.19
2.28
PFCF 21.52
AMED's PFCF is ranked lower than
51% of the 112 Companies
in the Global Medical Care industry.

( Industry Median: 20.97 vs. AMED: 21.52 )
Ranked among companies with meaningful PFCF only.
AMED' s PFCF Range Over the Past 10 Years
Min: 2.95  Med: 10.85 Max: 87.98
Current: 21.52
2.95
87.98
POCF 16.23
AMED's POCF is ranked lower than
58% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 13.59 vs. AMED: 16.23 )
Ranked among companies with meaningful POCF only.
AMED' s POCF Range Over the Past 10 Years
Min: 2.02  Med: 6.52 Max: 23.15
Current: 16.23
2.02
23.15
EV-to-EBIT 23.53
AMED's EV-to-EBIT is ranked lower than
59% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 19.36 vs. AMED: 23.53 )
Ranked among companies with meaningful EV-to-EBIT only.
AMED' s EV-to-EBIT Range Over the Past 10 Years
Min: -177  Med: 7.20 Max: 2214.4
Current: 23.53
-177
2214.4
EV-to-EBITDA 19.05
AMED's EV-to-EBITDA is ranked lower than
65% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 13.84 vs. AMED: 19.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.8  Med: 6.70 Max: 65
Current: 19.05
-6.8
65
Current Ratio 0.88
AMED's Current Ratio is ranked lower than
73% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 1.35 vs. AMED: 0.88 )
Ranked among companies with meaningful Current Ratio only.
AMED' s Current Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.99 Max: 2.88
Current: 0.88
0.33
2.88
Quick Ratio 0.88
AMED's Quick Ratio is ranked lower than
69% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 1.23 vs. AMED: 0.88 )
Ranked among companies with meaningful Quick Ratio only.
AMED' s Quick Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.99 Max: 2.85
Current: 0.88
0.31
2.85
Days Sales Outstanding 42.30
AMED's Days Sales Outstanding is ranked higher than
52% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 43.55 vs. AMED: 42.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.1  Med: 36.50 Max: 54.01
Current: 42.3
30.1
54.01
Days Payable 16.22
AMED's Days Payable is ranked lower than
80% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 37.56 vs. AMED: 16.22 )
Ranked among companies with meaningful Days Payable only.
AMED' s Days Payable Range Over the Past 10 Years
Min: 8.33  Med: 12.00 Max: 22.23
Current: 16.22
8.33
22.23

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 21.07
AMED's Price/Tangible Book is ranked lower than
96% of the 165 Companies
in the Global Medical Care industry.

( Industry Median: 3.56 vs. AMED: 21.07 )
Ranked among companies with meaningful Price/Tangible Book only.
AMED' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.2  Med: 4.31 Max: 1700
Current: 21.07
0.2
1700
Price/Projected FCF 2.25
AMED's Price/Projected FCF is ranked lower than
66% of the 91 Companies
in the Global Medical Care industry.

( Industry Median: 1.73 vs. AMED: 2.25 )
Ranked among companies with meaningful Price/Projected FCF only.
AMED' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.16  Med: 1.31 Max: 12.29
Current: 2.25
0.16
12.29
Price/Median PS Value 1.63
AMED's Price/Median PS Value is ranked lower than
83% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 1.04 vs. AMED: 1.63 )
Ranked among companies with meaningful Price/Median PS Value only.
AMED' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.65 Max: 2.6
Current: 1.63
0.11
2.6
Price/Peter Lynch Fair Value 0.70
AMED's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 46 Companies
in the Global Medical Care industry.

( Industry Median: 2.20 vs. AMED: 0.70 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMED' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.21  Med: 0.72 Max: 3.24
Current: 0.7
0.21
3.24
Price/Graham Number 6.45
AMED's Price/Graham Number is ranked lower than
92% of the 116 Companies
in the Global Medical Care industry.

( Industry Median: 2.38 vs. AMED: 6.45 )
Ranked among companies with meaningful Price/Graham Number only.
AMED' s Price/Graham Number Range Over the Past 10 Years
Min: 1.05  Med: 2.49 Max: 20
Current: 6.45
1.05
20
Earnings Yield (Greenblatt) (%) 4.25
AMED's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 4.10 vs. AMED: 4.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMED' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 9.20 Max: 33.9
Current: 4.25
0.1
33.9
Forward Rate of Return (Yacktman) (%) 34.75
AMED's Forward Rate of Return (Yacktman) (%) is ranked higher than
92% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 10.71 vs. AMED: 34.75 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMED' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7  Med: 40.80 Max: 109.3
Current: 34.75
7
109.3

More Statistics

Revenue (TTM) (Mil) $1,328
EPS (TTM) $ 1.15
Beta0.48
Short Percentage of Float5.89%
52-Week Range $28.71 - 54.29
Shares Outstanding (Mil)33.42

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 1,444 1,513
EPS ($) 1.74 2.11
EPS without NRI ($) 1.74 2.11
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
» More Articles for AMED

Headlines

Articles On GuruFocus.com
“Powerball” Ideas - Home Healthcare Companies: AFAM, GTIV, LHCG, AMED Jan 05 2012 
AMED: Investment Opportunity When the Price Hits an 8-Year Low Dec 27 2011 
Almost Family: The Magic Formula Stock is getting cheaper and cheaper Dec 11 2011 
Magic Formula Stock: Amedisys (AMED) Aug 05 2011 
Home Healthcare: Heavily Shorted long Opportunity May 30 2011 
Amedisys Inc (AMED) CFO Dale E Redman buys 1,000 Shares Aug 25 2010 
Amedisys Inc Reports Operating Results (10-Q) Aug 09 2010 
Amedisys Inc Reports Operating Results (10-Q) Apr 27 2010 
Amedisys Inc (AMED) Chairman of the Board William F Borne sells 25,000 Shares Feb 24 2010 
Amedisys Inc (AMED) Chairman of the Board William F Borne sells 12,500 Shares Dec 29 2009 

More From Other Websites
ETF’s with exposure to Amedisys, Inc. : May 19, 2016 May 19 2016
Amedisys, Inc. :AMED-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
Amedisys to Present at the Bank of America Merrill Lynch Health Care Conference May 06 2016
Amedisys to Present at the Bank of America Merrill Lynch Health Care Conference May 06 2016
Amedisys (AMED) Lags Q1 Earnings, Revenues Top the Mark May 06 2016
Edited Transcript of AMED earnings conference call or presentation 4-May-16 3:00pm GMT May 04 2016
AMEDISYS INC Files SEC form 10-Q, Quarterly Report May 04 2016
Amedisys Inc Earnings Call scheduled for 11:00 am ET today May 04 2016
Amedisys Reports First Quarter Financial Results May 03 2016
Amedisys Reports First Quarter Financial Results May 03 2016
AMEDISYS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... May 03 2016
Q1 2016 Amedisys Inc Earnings Release - After Market Close May 03 2016
AMEDISYS INC Files SEC form 8-K, Entry into a Material Definitive Agreement May 02 2016
Amedisys Announces First Quarter Earnings Release and Conference Call Date Apr 26 2016
Amedisys Announces First Quarter Earnings Release and Conference Call Date Apr 26 2016
Amedisys Welcomes Three New Members To Its Board Of Directors Apr 26 2016
AMEDISYS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles... Apr 26 2016
Amedisys Welcomes Three New Members To Its Board Of Directors Apr 26 2016
ETF’s with exposure to Amedisys, Inc. : April 19, 2016 Apr 19 2016
Amedisys Poised To Help Baby Boomers ‘Age In Place’ Apr 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)